Bacillus subtilis intestinal colonization strain for expressing recombinant interferon in pig body and application of bacillus subtilis intestinal colonization strain

By recombining the porcine-derived interferon gene with the pHT-43 plasmid to Bacillus subtilis, the secretion and stable expression of large amounts of interferons without induction are achieved, and the problems of low expression and degradation in the prior art are solved, and long-term immune protection in pigs is provided and therapeutic effects.

CN118909904AInactive Publication Date: 2024-11-08SHANDONG AGRICULTURAL UNIVERSITY
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411388088.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-08
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing methods of using Bacillus subtilis to express interferon in pigs have problems such as inapplicable plasmids, poor promoter matching, difficulty in purification and preparation, induction of exogenous expression, and degradation in the intestinal tract after oral administration, which reduces treatment. Effects of immunosuppressive diseases.

Method used

By recombining the codon-optimized pig-derived interferon gene with the pHT-43 modified plasmid, electrotransformed into Bacillus subtilis, obtaining the intestinal colonization strain of Bacillus subtilis that secretes recombinant interferon, and directly colonizes it in the pig body. Bacillus subtilis' own P43 promoter achieves non-induced massive secretion and stable expression.

Benefits of technology

The long-term stable expression of interferon in pigs is achieved, the level of interferon intestinal tract is improved, long-term or lifelong immune protection against the virus, reduced production and use costs, and improved therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909904A_ABST
    Figure CN118909904A_ABST
Patent Text Reader

Abstract

The invention provides a bacillus subtilis intestinal colonization strain for expressing recombinant interferon in a pig body and application of the bacillus subtilis intestinal colonization strain, and belongs to the technical field of genetic engineering biology. According to the invention, a pHT-43 plasmid is modified, and an inducible promoter of the pHT-43 is replaced by a P43 promoter existing in bacillus subtilis, so that the plasmid can secrete a large amount of interferon in the intestinal tract of a pig without induction; the secreted interferon can play a role in the intestinal tract and can also be absorbed by the intestinal tract to improve the interferon level of the whole body, so that the antiviral effect is achieved. The bacillus subtilis intestinal colonization strain for secreting and expressing the recombinant interferon prepared by the invention can be directly and stably colonized in a pig body, and the interferon is continuously generated in the pig body along with the replication and expression of the colonization strain, so that the difficulty in manufacturing the interferon in vitro is eliminated, the production cost and the use cost are reduced, and the production efficiency is improved. And the host can obtain long-term or lifelong immunization on the virus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of genetic engineering biotechnology, and in particular relates to a Bacillus subtilis intestinal colonization strain expressing recombinant interferon in pigs and a use thereof. Background Art

[0002] Active substances such as subtilisin, polymyxin, nystatin, and gramicidin produced during the growth of Bacillus subtilis have a significant inhibitory effect on pathogenic bacteria or conditional pathogens of endogenous infection. Bacillus subtilis promotes spore formation and microencapsulation of special bacteria. It has good stability in the spore state, is resistant to oxidation and extrusion, and can withstand high temperatures of 60°C for a long time. It can survive for 20 minutes at 120°C. It is resistant to acid and alkali, can maintain activity in the acidic environment of the stomach, can withstand the attack of saliva and bile, and is a live bacterium that can reach the large and small intestines 100%.

[0003] Interferon is a highly active multifunctional glycoprotein produced by macrophages, lymphocytes and somatic cells stimulated by viruses or other factors. The research on interferon has a history of more than 50 years. The great progress made in the research of interferon in biological genetic engineering has greatly promoted the reform of interferon production technology. At present, it is mainly used for the prevention and treatment of porcine epidemic diarrhea, infectious gastroenteritis, rotavirus infection, swine fever, blue ear disease, circovirus, pseudorabies, swine influenza, vesicular disease, parvovirus disease, etc., and has outstanding effects on the prevention and treatment of immunosuppressive diseases in pigs.

[0004] With the development of biotechnology and genetic engineering technology, the biotechnology of gene expression of recombinant interferon is now quite mature. Although a large number of interferons produced by engineered bacteria have been put on the market, they are still affected by various conditions during the production and processing, such as the need to improve the fermentation system and simplify the purification process, the need to improve the yield and quality, and the need to make preparations and transportation costs. In order to reduce the economic burden, continuous improvement is still needed. The existing method of using Bacillus subtilis to express porcine interferon also has problems, such as the selected plasmid is not suitable for Bacillus subtilis plasmid, the promoter in the plasmid is not the Bacillus subtilis promoter, and the interferon expression level produced is low. The expressed interferon needs to be purified, prepared into preparations for transportation, and the storage conditions and use process may cause the effect to decrease.

[0005] In addition, the existing engineered bacteria that express recombinant interferon are basically exogenously expressed and can only secrete interferon in large quantities under induction. Exogenously expressed interferon is mostly administered by injection. When fed to animals orally, the interferon will be degraded before reaching the animal's intestines, resulting in a reduction in the amount of interferon that actually works in the intestines or is absorbed and utilized by the intestines, thereby reducing the effect of treating immunosuppressive diseases. Summary of the invention

[0006] In view of the problems existing in the above-mentioned prior art, the purpose of the present invention is to provide a Bacillus subtilis intestinal colonization strain expressing recombinant interferon in pigs and its use. The present invention obtains a Bacillus subtilis intestinal colonization strain that secretes and expresses recombinant interferon by recombining the codon-optimized porcine interferon gene with the pHT-43 modified plasmid and electrotransforming it into Bacillus subtilis. The strain can be directly colonized in the pig body, so that the interferon level in the host body is in the best state for a long time, thereby obtaining long-term or lifelong immunity to the virus.

[0007] In order to solve the above technical problems, the present invention adopts the following technical solutions: In a first aspect, the present invention provides a pHT-43 modified plasmid, wherein the pHT-43 modified plasmid is obtained by replacing the inducible promoter in the pHT-43 plasmid with the P43 promoter shown in SEQ ID NO.1.

[0008] The second aspect of the present invention provides the use of the above-mentioned pHT-43 modified plasmid in the preparation of a colonization strain that can stably colonize in the intestine and secrete interferon.

[0009] In a third aspect, the present invention provides a Bacillus subtilis intestinal colonization strain expressing recombinant interferon in pigs, wherein the Bacillus subtilis intestinal colonization strain is prepared by the following method: (1) Connecting the porcine interferon gene to the above-mentioned pHT-43 modified plasmid to obtain a recombinant plasmid; (2) The recombinant plasmid was electroporated into Bacillus subtilis to obtain an intestinal colonization strain of Bacillus subtilis that secretes and expresses recombinant interferon.

[0010] The porcine interferon gene in step (1) is a codon-optimized porcine IFN-α interferon gene, and its nucleotide sequence is shown in SEQ ID NO.4.

[0011] The Bacillus subtilis in step (2) is Bacillus subtilis wb800n.

[0012] The intestinal colonization strain of Bacillus subtilis can be directly colonized in the pig body by drinking water, food addition, construction of biological preparations, etc., and interferon is continuously produced in the pig body as the intestinal colonization strain of Bacillus subtilis replicates and expresses.

[0013] In a fourth aspect, the present invention provides the use of the above-mentioned Bacillus subtilis intestinal colonization strain in the following (1) or (2): (1) Preparation of biological products with broad-spectrum antiviral effects; (2) Preparation of biological products with immunomodulatory effects.

[0014] The biological product is any one of oral liquid of Bacillus subtilis expressing recombinant interferon, enteric-coated capsules of Bacillus subtilis expressing recombinant interferon, tablets of Bacillus subtilis expressing recombinant interferon, lyophilized powder of Bacillus subtilis expressing recombinant interferon, cream of Bacillus subtilis expressing recombinant interferon, and powder of Bacillus subtilis expressing recombinant interferon.

[0015] In a fifth aspect, the present invention provides a lyophilized powder of Bacillus subtilis expressing recombinant interferon, wherein the lyophilized powder of Bacillus subtilis is prepared by the following method: The prepared Bacillus subtilis intestinal colonization strain expressing recombinant interferon in pigs is subcultured and then freeze-dried to reduce its water content to less than 3% to obtain freeze-dried Bacillus subtilis powder expressing recombinant interferon.

[0016] Beneficial effects of the present invention: 1. The pHT-43 plasmid used in the present invention is a secretory plasmid for Bacillus subtilis. The wb800n strain, which is more suitable for secretory expression of Bacillus subtilis, can secrete the expressed protein outside the bacteria. By modifying the pHT-43 plasmid, the inducible promoter of pHT-43 is replaced with the P43 promoter existing in Bacillus subtilis itself, so that the plasmid can secrete a large amount of interferon in the pig intestine without induction, and the secreted interferon can not only play a role in the intestine but also be absorbed through the intestine to improve the overall interferon level of the body, thereby playing an antiviral effect.

[0017] 2. The intestinal colonization strain of Bacillus subtilis that secretes and expresses recombinant interferon prepared by the present invention can be directly and stably colonized in pigs. As the colonized bacteria replicate and express in the pig, interferon is continuously produced, so that the interferon level in the host is in an optimal state for a long time. This not only eliminates the difficulties in the manufacture, transportation and use of interferon in vitro, reduces the production cost and use cost, but also enables the host to obtain long-term or lifelong immunity to viruses. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This is a schematic diagram of the invention principle.

[0019] Figure 2 This is PCR verification of successful plasmid transformation, and the negative control spot well is clear water.

[0020] Figure 3 This is the PCR verification diagram of bacterial solution.

[0021] Figure 4 This is the protein expression diagram verified by WB, where Figure 4 The middle spot well 1 is the soluble protein after bacterial lysis. Figure 4 The middle spot well 2 is the inclusion body protein after bacterial lysis. Figure 4The middle well 3 is the culture medium protein.

[0022] Figure 5 This is a diagram showing the inhibitory effect of IFN-α expressed by recombinant Bacillus subtilis on VSV.

[0023] Figure 6 The WB verification protein expression diagram of the two bacteria, Figure 6 The middle spot well 1 is the soluble protein after PHT-43-p43-IFN-α cleavage. Figure 6 The middle spot well 2 is the inclusion body protein after PHT-43-p43-IFN-α cleavage. Figure 6 The middle spot well 2 is PHT-43-p43-IFN-α culture medium protein, Figure 6 The middle spot well 4 is the soluble protein after PHT-43-IFN-α cleavage. Figure 6 The middle spot well 5 is the inclusion body protein after PHT-43-IFN-α cleavage. Figure 6 The middle well 6 is the PHT-43-IFN-α culture medium protein.

[0024] Figure 7 Figure 2. Antiviral activity assay results.

[0025] Figure 8 It is the animal experiment results and line graph; Figure 8 A in the middle is a line graph of blood IFN-α content; Figure 8 B is a line graph of interferon content in intestinal contents. DETAILED DESCRIPTION

[0026] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0027] The following detailed description is for illustrative purposes only and is intended to provide further explanation of the present application, rather than to limit the scope of the present invention.

[0028] The test materials used in the examples and comparative examples of the present invention are all conventional test materials in the art and can be purchased through commercial channels.

[0029] Example 1: Plasmid transformation Primers were designed based on the P43 promoter sequence in NCBI, and the pHT-43 plasmid promoter was replaced with the P43 promoter based on homologous recombination. The P43 promoter sequence is shown in SEQ ID NO.1, and the primer sequences used for homologous recombination are shown in SEQ ID NO.2-SEQ ID NO.3: P43 promoter sequence (SEQ ID NO.1): TGATAGGTGGTATGTTTTCGCTTGAACTTTAAATACAGCCATTGAACATACGGTTGATTTAATAACTGACAAACATCACCCTCTTGCTAAAGCGGCCAAGGACGCTGCCGCCGGGGCTGTTTGCGTTTTTGCCGTGATTTCGTGTATCA TTGGTTTACTTATTTTTTTGCCAAAGCTGTAATGGCTGAAAATTCTTACATTTATTTTACATTTTTAGAAATGGGCGTGAAAAAAAGCGCGCGATTATGTAAAATATAAAGTGATAGCGGTACCATTATAGGTAAGAGAGGAACGTACAC P43-F (SEQ ID NO.2): ATTAATTGCGTTGCGCTGATAGGTGGTATG P43-R (SEQ ID NO.3): TCCTTCCTCCTTTAATTGGTGTACGTTCCTCTC The EcoRⅤ and ApaⅠ restriction sites of PHT-43 plasmid were double-digested, and after gel recovery, the plasmid was connected to the P43 promoter by homologous recombination. The transformed plasmid was transferred into DH5α competent state by heat stimulation and evenly coated on a solid culture dish containing 50μg / mL AMP resistance LB. The bacteria were cultured overnight for verification, and the P43-F and P43-R primers were used for verification and sequencing to obtain the successfully transformed positive plasmid ( Figure 2 ), amplify the positive plasmid. Extract the plasmid for later use.

[0030] Example 2: Preparation of recombinant plasmid The porcine IFN-α gene (NCBI No.: MH115424.1) was codon optimized to obtain the optimized IFN-α interferon genome sequence SEQ ID NO.4.

[0031] Optimized IFN-α interferon genome sequence (SEQ ID NO.4): ATGTGCGATCTGCCGCAAACACATAGCCTGGCACATACAAGAGCACTGAGACTGCTTGCACAAATGAGAAGAATTTCACCGTTTTCATGCCTGGATCATAGAAGAGATTTTGGCTCACCGCATGAAGCATTTGGCGGCAATCAAGTTCAAAAAGCACAAGCAATGGCACTGGTTCATGAAATGCTGCAACAAACATTTCAACTGTTTTCAACAGAAGGCAGCGCAGCAGCATGGAATGAATCACTGCTGC ATCAATTTTGCACAGGCCTGGATCAACAACTGAGAGATCTGGAAGCATGCGTTATGCAAGAAGCAGGCCTGGAAGGCACAACCGCTGCTGGAAGAAGATAGCATTCTGGCAGTTAGAAAATATTTTCATAGACTGACACTGTATCTGCAAGAAAAATCATATTCACCGTGCGCATGGGAAATTGTTAGAGCAGAAGTTATGAGAAGCTTTAGCTCAAGCAGAAATCTGCAAGATAGACTGCGCAAAAAAGAA The modified plasmid prepared in Example 1 and the optimized porcine IFN-α gene with added restriction sites were double-digested with XbaⅠ and BamHI, and interferon T4 connecting primers SEQ ID NO.5-SEQ ID NO.6 were designed according to the gene sequence after codon optimization, wherein IFN-α-F (SEQ ID NO.5): GGATCCATGTGCGATCTGCCG; IFN-α-R (SEQ ID NO.6): CTGCGCAAAAAAGAATCTAGA.

[0032] After the modified plasmid and the optimized porcine IFN-α gene were integrated by T4 ligase to form a recombinant plasmid, the recombinant plasmid was transferred into DH5α competent cells by heat stimulation to amplify the recombinant plasmid. The recombinant plasmid was extracted for later use.

[0033] Example 3: Preparation of competent Bacillus subtilis The configuration method of electroporation medium A is shown in Table 1: Table 1: Preparation of electroporation medium A The configuration method of electroporation medium B is shown in Table 2: Table 2: Preparation of electroporation medium B Inoculate wb800n Bacillus subtilis into electroporation medium A and culture in a 37℃ 5% CO2 incubator until OD 600 When the pH is 0.6-0.8, transfer to a sterile pre-cooled 50ml centrifuge tube and place on ice for 10 minutes. After centrifugation at 4℃, 5000r for 5 minutes, collect the bacterial precipitate, add pre-cooled electrotransfer medium B to the precipitate, resuspend the bacteria, centrifuge at 4℃, 5000r for 5 minutes, collect the precipitate, and repeat four times. Finally, add 3ml electrotransfer medium B to resuspend the washed bacteria, and store at -80℃ after aliquoting.

[0034] Example 4: Preparation of Bacillus subtilis expressing recombinant interferon The configuration method of electroporation recovery medium is shown in Table 3: Table 3: Preparation of electroporation recovery medium Soak the electroporation cup (2 mm) in 75% alcohol for >5 h, dry it and precool it, take 100 μl of the wb800n Bacillus subtilis competent prepared in Example 3, add 10 μl of the recombinant plasmid prepared in Example 2, incubate it in an ice box for 2 min, and then add it to the electroporation cup.

[0035] The electroporation procedure is shown in Table 4: Table 4: Electroporation Procedure After the electroporation is completed, add 1 ml of electroporation recovery medium immediately, mix gently, transfer into a 1.5 ml centrifuge tube and shake at 220r at 37°C for 3 h.

[0036] Centrifuge (1000r, 1min) and discard 800μl supernatant, resuspend the bacteria, evenly spread on LB solid medium containing 50ug / ml chloramphenicol and culture overnight. The next day, pick bacteria for PCR verification ( Figure 3 ), retain the positive single colony.

[0037] Example 5: Expression of interferon by Bacillus subtilis and antiviral testing 1. Expression of interferon and antiviral test of the intestinal colonization strain of Bacillus subtilis secreting and expressing recombinant interferon prepared by the present invention (1) Add the Bacillus subtilis expressing recombinant interferon into new LB liquid culture medium at a ratio of 1:1000, shake the culture for 36 hours, and then centrifuge (4°C, 8000r, 10min) to separate the culture medium and Bacillus subtilis. Resuspend the Bacillus subtilis in PBS and wash it by centrifugation again. Resuspend and lyse the Bacillus subtilis with 5 times the volume of PBS, and centrifuge (4°C, 13000r, 10min) to save the supernatant and precipitate after lysis.

[0038] (2) Add an equal volume of methanol to the collected culture medium, vortex to mix, add 1 / 4 volume of chloroform, vortex to mix, centrifuge (4°C, 13000r, 10min), transfer the protein in the boundary layer to a new 1.5ml tube, add 600μl of methanol, vortex to mix, centrifuge (4°C, 13000r, 10min), discard the supernatant, dry the precipitate, and resuspend it in PBS.

[0039] (3) Add 8 mol / L urea solution to the precipitate after lysis in step (1), place it in ice water, and place it in a refrigerator at 4°C for more than two hours to fully dissolve the inclusion body protein.

[0040] (4) WB detection of culture medium protein (obtained after treatment in step (2)), soluble protein in the supernatant after lysis, and interferon content in inclusion body protein after lysis, and the interferon content in the culture medium was the highest ( Figure 4 ), that is, Bacillus subtilis secretes interferon-α.

[0041] The culture medium of recombinant Bacillus subtilis was filtered, and 6-well plates of BHK cells were plated for 16 hours. The first well was added with 10μl VSV (preserved in the laboratory), the second well was added with 10μl VSV plus 500 ml of recombinant Bacillus subtilis culture medium, the third well was added with 10μl VSV plus 1000 ml of recombinant Bacillus subtilis culture medium, and the fourth well was added with water as a negative control. The results showed that the recombinant Bacillus subtilis culture medium had an antiviral effect ( Figure 5 ).

[0042] 2. Detection of interferon expression ability of different Bacillus subtilis intestinal colonization strains that secrete and express recombinant interferon In order to verify whether the interferon expression ability of the intestinal colonization strain of Bacillus subtilis obtained by recombining the codon-optimized porcine interferon gene with the pHT-43 modified plasmid and electrotransforming it into Bacillus subtilis that secretes and expresses recombinant interferon is improved, comparative example 1 is set. The strain preparation method provided in comparative example 1 is as follows: Comparative Example 1: Compared with the method for preparing the intestinal colonization strain of Bacillus subtilis that secretes and expresses recombinant interferon of the present invention, the only difference is that the pHT-43 plasmid used is not modified, and the PHT-43-IFN-α Bacillus subtilis is prepared.

[0043] The PHT-43-IFN-α Bacillus subtilis bacterial solution prepared in Comparative Example 1 and the bacterial solution of the Bacillus subtilis intestinal colonization strain (PHT-43-p43-IFN-α Bacillus subtilis) prepared in the present invention that secretes and expresses recombinant interferon were added to LB liquid culture medium at a ratio of 1:1000, respectively, until the OD 6000.6-0.8, the comparative example 1 (PHT-43-IFN-α Bacillus subtilis) group was added with IPTG to a final concentration of 1 mmol / L to induce expression for 5 h, the present invention (PHT-43-p43-IFN-α Bacillus subtilis) group was not added with IPTG and only shaken for 5 h, and the culture medium protein of the two groups with a sample volume of 12 μL, the soluble protein in the supernatant after lysis, and the interferon expression in the inclusion body protein after lysis were detected by WB.

[0044] The test results show that the intestinal colonization strain of Bacillus subtilis expressing recombinant interferon obtained by modifying the pHT-43 plasmid of the present invention has a higher interferon content in the culture medium protein than the interferon content of PHT-43-IFN-α Bacillus subtilis obtained in the comparative example 1 under the induction condition without IPTG induction ( Figure 6 ).

[0045] Example 6: Detection of interferon concentration and antiviral activity secreted by Bacillus subtilis (1) Add the stored Bacillus subtilis expressing recombinant interferon into new LB liquid culture medium at a ratio of 1:1000, shake the culture for 36 hours, and then centrifuge (4°C, 8000r, 10min) to separate the culture medium and Bacillus subtilis. Use a commercially available porcine interferon-α ELISA detection kit (Jiang Lanchun) to detect the interferon-α concentration in the culture medium. Repeat the test three times, and the interferon concentration is the average of the three tests: (146.32pg / ml+163.83pg / ml+118.31pg / ml) / 3=142.82pg / ml).

[0046] (2) Prepare a 96-well plate, plate BHK cells on the 96-well plate for 16 hours to allow the cells to adhere to the wall, dilute the culture medium obtained in step (1) by 10 times in a gradient manner, and add 100 μl of the BHK cells pretreated for 24 hours (the first well contains 100 μl of blank liquid LB culture medium as a negative control, wells 2-11 in each row contain gradient dilution culture medium, and well 12 contains undiluted VSV virus plus 100 μl of blank liquid LB culture medium as a positive control, with four rows for four replicates). Each well is inoculated with 100×TCID 50 VSV virus solution, four groups were repeated, and more than half of the area of ​​each well was judged as a positive well if it showed fluorescence, less than half of the area or no fluorescence was judged as a negative well. When more than half of the control group was positive, the dilution factor was 10. 5 When more than half of the wells are positive, the interferon antiviral activity is 1.0×10 5 IU / ml( Figure 7 ).

[0047] Example 7: Preparation and resuscitation experiment of Bacillus subtilis freeze-dried powder Add Bacillus subtilis expressing recombinant interferon into LB liquid culture medium at a ratio of 1:1000, shake 1.5 l of the bacteria, centrifuge (4 ° C, 8000r, 10min), resuspend with deionized water and centrifuge again, resuspend in 75ml of deionized water and freeze-dry in a freeze dryer for 48h to make the water content of the strain <3%, collect 2.44g of freeze-dried powder, take 0.01g of freeze-dried powder and add 3ml of deionized water, absorb 30μl and apply it on AMP plate, observe after 24h and find that it is full of colonies, indicating that the freeze-dried powder is successfully revived, and store the rest of the freeze-dried powder in a dark place at 4 ° C.

[0048] Take 0.01g of freeze-dried powder and add it to 10ml of deionized water, dilute it by 10 times, spread it on the plate to count the colonies, repeat three times, and you will get 1g of freeze-dried powder can resuscitate about 6×10 8 A recombinant Bacillus subtilis.

[0049] Example 8: Mouse feeding experiment Since Bacillus subtilis has no species specificity, in order to facilitate the experiment, the model organism mouse was used to verify whether the intestinal colonization strain of Bacillus subtilis prepared by the present invention can colonize normally and express proteins.

[0050] The lyophilized powder prepared in Example 7 was dissolved in deionized water to prepare 0.01 g / mL intragastric bacterial solution. Twenty-four 8-week-old Kunming white mice were taken and divided into four different experimental groups. A negative control group (fed with an equal amount of water each time) was set up for feeding experiments.

[0051] Experimental group 1: After the start of the experiment, the rats were fed 0.5 mL of bacterial solution by gavage once a day, and the interferon levels in the cecal fluid and blood were measured after 1, 3, and 7 days (compared with the negative control); Experimental group 2: After the start of the experiment, the rats were fed 0.5 mL of bacterial solution twice a day, and the interferon content in the cecal fluid and the interferon content in the blood were detected after 1 day, 3 days, and 7 days respectively (compared with the negative control); Experimental group 3: After the start of the experiment, the rats were fed 0.5 mL of bacterial solution by intragastric administration once a day, and were allowed to drink water freely after intragastric administration. The interferon levels in the cecal fluid and blood were measured after 3 days, 7 days, and one month, respectively (compared with the negative control); Experimental Group 4: After the start of the experiment, the rats were fed 0.5 mL of bacterial solution by gavage once a day for a total of three times. They were allowed to drink water freely after gavage. The interferon levels in the cecal contents and blood were measured after 3 days, 7 days, and one month, respectively (compared with the negative control).

[0052] The test results showed that (Table 5, Figure 8): The interferon content in the cecal contents and blood of experimental groups 1 to 4 were significantly higher than those of the negative control. Colonizing the recombinant Bacillus subtilis into mice by feeding can significantly increase the interferon level in the mice.

[0053] Table 5: Detection of interferon content in cecal fluid and blood The above description is only a preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification made within the spirit and principle of the present application shall be deemed to be appropriate. Equivalent replacements, improvements, etc. should all be included in the protection scope of this application.

Claims

1. A Bacillus subtilis intestinal colonization strain expressing recombinant interferon in pigs, characterized in that: The Bacillus subtilis intestinal colonization strain is prepared by the following method: (1) Connecting the porcine interferon gene to the pHT-43 modified plasmid to obtain a recombinant plasmid; (2) The recombinant plasmid was electroporated into Bacillus subtilis to obtain an intestinal colonization strain of Bacillus subtilis that secretes and expresses recombinant interferon.

2. The Bacillus subtilis intestinal colonization strain according to claim 1, characterized in that The pHT-43 modified plasmid in step (1) is obtained by replacing the inducible promoter in the pHT-43 plasmid with the P43 promoter shown in SEQ ID NO.

1.

3. The Bacillus subtilis intestinal colonization strain according to claim 1, characterized in that The porcine interferon gene in step (1) is a codon-optimized porcine IFN-α interferon gene, and its nucleotide sequence is shown in SEQ ID NO.

4.

4. The Bacillus subtilis intestinal colonization strain according to claim 1, characterized in that The Bacillus subtilis in step (2) is Bacillus subtilis wb800n.

5. Use of the Bacillus subtilis intestinal colonization strain according to any one of claims 1 to 4 in the preparation of biological products with broad-spectrum antiviral effects.

6. Use of the intestinal colonization strain of Bacillus subtilis according to any one of claims 1 to 4 in the preparation of biological products with immunomodulatory effects.

7. The use according to claim 6, characterized in that: The biological product is any one of oral liquid of Bacillus subtilis expressing recombinant interferon, enteric-coated capsules of Bacillus subtilis expressing recombinant interferon, tablets of Bacillus subtilis expressing recombinant interferon, lyophilized powder of Bacillus subtilis expressing recombinant interferon, cream of Bacillus subtilis expressing recombinant interferon, and powder of Bacillus subtilis expressing recombinant interferon.

8. A lyophilized powder of Bacillus subtilis expressing recombinant interferon, characterized in that: The Bacillus subtilis freeze-dried powder is prepared by the following method: The intestinal colonization strain of Bacillus subtilis expressing recombinant interferon in pigs according to claim 1 is subcultured and then freeze-dried to reduce its water content to less than 3% to obtain freeze-dried powder of Bacillus subtilis expressing recombinant interferon.

Citation Information

Patent Citations

  • Method for preparing porcine alpha-interferon

    CN101434958A

  • Recombined porcine interferon alpha 1, as well as gene encoding gene and expression method thereof

    CN103059122A

  • Method for efficiently expressing porcine defensin by utilizing bacillus subtitles

    CN106148381A

  • Recombinant bacillus subtilis engineering bacterium producing pig epidermal growth factor (pEGF) and application

    CN110172433A

  • Bacillus subtilis for expressing SAT2 type foot and mouth disease virus structural protein VP3 and application

    CN114921397A